中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

64 records (took 0.026 seconds)

    METHODS OF TREATING HIV-ASSOCIATED NEUROLOGICAL DISORDERS (HAND)
    21.
    发明申请
    METHODS OF TREATING HIV-ASSOCIATED NEUROLOGICAL DISORDERS (HAND) 有权

    公开(公告)号：US20220184036A1

    公开(公告)日：2022-06-16

    申请号：US17547472

    申请日：2021-12-10

    Applicant: Rosalind Franklin University of Medicine and Science

    Inventor： Johnny HE ,  Xiaojie ZHAO

    IPC: A61K31/41 ,  A61K45/06 ,  A61P25/00 ,  A61K31/506

    Abstract: In the present disclosure, doxycycline-inducible astrocyte-specific HIV Tat transgenic mice (iTat), a surrogate HAND model, were treated with PNU-125096, a positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR) and effects on Tat-induced behavioral impairments and neuropathologies were observed. This disclosure shows that PNU-125096 treatment significantly improved locomotor, learning and memory deficits of iTat mice while inhibited glial activation and increased PSD-95 expression in the cortex and hippocampus of iTat mice. α7 nAChR knockout eliminated the protective effects of PNU-125096 on iTat mice. In addition, inhibition of p38 phosphorylation by SB239063, a p38 MAPK-specific inhibitor, exacerbated Tat neurotoxicity in iTat mice. These findings demonstrated for the first time that α7 nAChR activation led to protection against HAND and suggest that α7 nAChR and PNU-125096 hold significant promise for development of therapeutics for HAND.

    Intelligent offloading insole device
    23.
    发明授权
    Intelligent offloading insole device 有权

    公开(公告)号：US10721993B2

    公开(公告)日：2020-07-28

    申请号：US15813613

    申请日：2017-11-15

    Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE ,  THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

    Inventor： Noah J. Rosenblatt ,  Ryan Crews ,  Farid Amirouche

    IPC: A43B17/03 ,  A43B13/20 ,  A43B3/00 ,  A43B17/02 ,  G05B15/02

    Abstract: A plantar surface pressure offloading system includes an insole capable of coupling with a shoe and interfacing with a foot. A number of compressible bladders and pressure sensors are coupled to the insole. Each bladder has an adjustable compressibility, and each pressure sensor is configured to measure a pressure exerted on a respective portion of the foot. A controller of the system can perform, for each compressible bladder, a compressibility adjustment process including (i) receiving, from a respective pressure sensor associated with a respective bladder, a signal indicative of a pressure exerted on a respective portion of the foot, (ii) determining, based on the signal, that the pressure exerted on the respective portion of the foot exceeds a threshold pressure, and (iii) responsive to the determination, adjusting the compressibility of the respective bladder, thereby offloading pressure from the respective portion of the foot to a different portion of the foot.

    Antisense compounds targeting genes associated with cystic fibrosis
    24.
    发明授权
    Antisense compounds targeting genes associated with cystic fibrosis 有权

    公开(公告)号：US10544417B2

    公开(公告)日：2020-01-28

    申请号：US15835995

    申请日：2017-12-08

    Applicant: Rosalind Franklin University of Medicine and Science

    Inventor： Michelle L. Hastings

    IPC: C12N15/113

    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

    Antisense compounds targeting genes associated with cystic fibrosis
    25.
    发明授权
    Antisense compounds targeting genes associated with cystic fibrosis 有权

    公开(公告)号：US10525076B2

    公开(公告)日：2020-01-07

    申请号：US15835698

    申请日：2017-12-08

    Applicant: Rosalind Franklin University of Medicine and Science

    Inventor： Michelle L. Hastings

    IPC: A61K31/712 ,  C12N15/113

    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

    Methods and kits for diagnosing, prognosing and monitoring parkinson's disease
    27.
    发明授权
    Methods and kits for diagnosing, prognosing and monitoring parkinson's disease 有权

    公开(公告)号：US09970056B2

    公开(公告)日：2018-05-15

    申请号：US14870960

    申请日：2015-09-30

    Applicant: Rosalind Franklin University of Medicine and Science

    Inventor： Judith Ann Potashkin ,  Jose Alfredo Santiago

    IPC: C12Q1/68

    CPC classification number: C12Q1/6883 ,  C12Q2600/158

    Abstract: Network-based meta-analysis of four independent microarray studies identified the hepatocyte nuclear factor (HNF4A), a transcription factor associated with gluconeogenesis and diabetes, as a central regulatory hub gene upregulated in blood of PD patients. In parallel, the polypyrimidine tract binding protein 1 (PTBP1), involved in the stabilization and mRNA translation of insulin, was identified as the most downregulated gene. Using both markers, PD patients were classified with 90% sensitivity and 80% specificity. Longitudinal performance analysis demonstrated that relative abundance of HNF4A and PTBP1 mRNAs significantly decreased and increased, respectively, in PD patients during 3 years follow up period. The inverse regulation of HNF4A and PTBP1 provides a molecular rationale for the altered insulin signaling observed in PD patients. The longitudinally dynamic biomarkers identified in this study may be useful for monitoring disease-modifying therapies for PD.

    ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH CYSTIC FIBROSIS
    28.
    发明申请
    ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH CYSTIC FIBROSIS 审中-公开

    公开(公告)号：US20180119152A1

    公开(公告)日：2018-05-03

    申请号：US15835995

    申请日：2017-12-08

    Applicant: Rosalind Franklin University of Medicine and Science

    Inventor： Michelle L. HASTINGS

    IPC: C12N15/113

    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

Patent Agency Ranking